Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STC314 in Sepsis
NCT06548854Phase 2Active, not recruiting
- Sponsor
- Grand Medical Group AG
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of STC3141 in sepsis (3 arms), sponsored by Grand Medical Group AG. Primary endpoint: Changes in Sequential Organ Failure Assessment (SOFA) scores from baseline at Day 7. Started Nov 2023; status: active, not recruiting.
02
Drugs
STC3141
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06548854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548854.